Barclays analyst Geoff Meacham says his survey of community and academic based hematologists/oncologists were in-line with his initial expectations of positive uptake for Seattle Genetics' Adcetris. The analyst conducted the survey to learn current prescribing habits and the likely impact of the Adcetris label expansion amid "continued skepticism." Meacham believes overall penetration of the Adcetris plus AVD regimen is likely to reach 32% in a year, up from 20% currently. He notes the Hodgkin's lymphoma survey confirmed his positive outlook on Seattle Genetics. The analyst has an Overweight rating on the shares with a $74 price target.